论文部分内容阅读
目的:探究n 68Ga-前列腺特异性膜抗原(PSMA)-11 PET/CT代谢体积参数在不同风险分层的初诊前列腺癌（PCa）患者中的差异。n 方法:回顾性分析2019年1月至12月于海军军区大学第一附属医院经前列腺活体组织穿刺检查结果确诊后行n 68Ga-PSMA-11 PET/CT检查的85例未经治疗的PCa患者的影像及临床资料，患者年龄49~88 (69.1±7.7）岁。根据是否发生肿瘤转移和美国国立综合癌症网络指南推荐的风险分层将患者分别分为无转移组和转移组、低中风险组和高风险组；以格里森评分（GS）8分为临界值，将患者分为GS20 ng/mL组；根据临床分期的不同，将患者分为临床T1~T2期组和临床T3~T4期组。采用三维勾画法在n 68Ga-PMSA-11 PET/CT图像上自动测量和勾画肿瘤病灶感兴趣区，计算最大标准化摄取值（SUVn max）、原发PSMA肿瘤体积（PSMA-TVn 原发）、全身PSMA肿瘤体积（PSMA-TVn 全身）、原发PSMA肿瘤总量（TL-PSMAn 原发）、全身PSMA肿瘤总量（TL-PSMAn 全身）。组间代谢体积参数的比较采用两独立样本非参数Mann-Whitney秩和检验。n 结果:85例患者n 68Ga-PSMA-11 PET/CT显像结果均呈阳性，其中无转移组46例（54.1%）、转移组39例（45.9%）；低中风险组15例（17.6%）、高风险组70例（82.4%）。转移组的SUVn max、PSMA-TVn 原发、PSMA-TVn 全身、TL-PSMAn 原发、TL-PSMAn 全身的中位数均高于无转移组（16.2对9.8，39.5 cmn 3对10.8 cmn 3，58.8 cmn 3对10.8 cmn 3，318.4 cmn 3对37.2 cmn 3，628.0 cmn 3对37.2 cmn 3），且差异均有统计学意义（n Z=-6.301~ -2.580，均n P<0.05）；高风险组的SUVn max、PSMA-TVn 原发、PSMA-TVn 全身、TL-PSMAn 原发、TL-PSMAn 全身的中位数均高于低中风险组（13.8对4.2，16.5 cmn 3对8.4 cmn 3，21.9 cmn 3对11.4 cmn 3，146.1 cmn 3对27.4 cmn 3，229.6 cmn 3对28.6 cmn 3），且差异均有统计学意义（n Z=-4.242~-2.438，均n P<0.05）；GS≥8分组的SUVn max、PSMA-TVn 原发、PSMA-TVn 全身、TL-PSMAn 原发、TL-PSMAn 全身的中位数均高于GS<8分组（14.8对9.9，16.5 cmn 3对12.5 cmn 3，23.9 cmn 3对14.3 cmn 3，146.1 cmn 3对36.3 cmn 3，229.6 cmn 3对36.3 cmn 3），除PSMA-TVn 原发外，差异均有统计学意义（n Z=-2.850~ -2.074，均n P20 ng/mL组的SUVn max、PSMA-TVn 原发、PSMA-TVn 全身、TL-PSMAn 原发、TL-PSMAn 全身的中位数均高于PSA≤20 ng/mL组（16.2对6.4，24.7 cmn 3对8.2 cmn 3，41.4 cmn 3对10.2 cmn 3，253.9 cmn 3对28.0 cmn 3，361.5 cmn 3对29.7 cmn 3），且差异均有统计学意义（n Z=-6.279~ -3.948，均n P<0.001）；临床T3~T4期组的SUVn max、PSMA-TVn 原发、PSMA-TVn 全身、TL-PSMAn 原发、TL-PSMAn 全身的中位数均高于临床T1~T2期组（16.6对9.3，34.9 cmn 3对10.7 cmn 3，62.3 cmn 3对14.3 cmn 3，303.5 cmn 3对32.6 cmn 3，482.1 cmn 3对45.9 cmn 3），且差异均有统计学意义（n Z=-4.889~ -3.629，均n P<0.001）。n 结论:转移组和高风险组的初诊前列腺癌患者n 68Ga-PSMA-11 PET/CT的代谢体积参数显著高于无转移组及低中风险组患者。n “,”Objective:To explore significant differences in the metabolic volume parameters of prostate specific membrane antigen labeled with n 68Gallium (n 68Ga-PSMA-11) PET/CT among different risk stratification subgroups in patients with newly diagnosed prostate carcinoma (PCa).n Methods:The images and clinical data of 85 untreated patients with PCa (aged 49-88 (69.1±7.7) years) newly diagnosed by prostate biopsy and examined by n 68Ga-PSMA-11 PET/CT in the First Affiliated Hospital of Naval Military Medical University from January 2019 to December 2019 were analyzed retrospectively. In accordance with the occurrence of tumor metastasis and the risk stratification recommended by the guidelines of National Comprehensive Cancer Network, patients were divided into binary subgroups: non-metastasis and metastasis subgroups as well as low-medium-and high-risk subgroups. Taking the Gleason score (GS)=8 as the critical value, patients were divided into GS20 ng/mL subgroups. In accordance with clinical stage, patients were divided into clinical T1-T2 and T3-T4 subgroups. Three dimensional sketching method was used to automatically measure and sketch the region of interest of tumor lesions onn 68Ga-PSMA-11 PET/CT images, and calculate the maximum standardized uptake value (SUVn max), primary PSMA tumor volume (PSMA-TVn primary), whole-body PSMA tumor volume (PSMA-TVn whole body), total number of primary PSMA tumors (TL-PSMAn primary), and total number of whole-body PSMA tumors (TL-PSMAn whole body) separately. The metabolic volume parameters between subgroups were compared by the nonparametric Mann-Whitney n U rank sum test of two independent samples.n Results:The results of n 68Ga-PSMA-11 PET/CT were positive in all 85 patients, including 46 cases (54.1%) in the non-metastasis subgroup and 39 cases (45.9%) in the metastasis subgroup as well as 15 cases (17.6%) in the low-medium-risk subgroup and 70 cases (82.4%) in the high-risk subgroup. The SUVn max, PSMA-TVn primary, PSMA-TVn whole body, TL-PSMAn primary, and TL-PSMAn whole body in the metastasis subgroup were significantly higher than those in the non-metastasis subgroup (16.2 n vs. 9.8, 39.5 cmn 3vs. 10.8 cmn 3, 58.8 cmn 3vs. 10.8 cmn 3, 318.4 cmn 3vs. 37.2 cmn 3, 628.0 cmn 3vs. 37.2 cmn 3; n Z=-6.301 to-2.580, all n P<0.05). The SUVn max, PSMA-TVn primary, PSMA-TVn whole body, TL-PSMAn primary, and TL-PSMAn whole body in the high-risk subgroup were significantly higher than those in the low-mediumrisk subgroup (13.8 n vs. 4.2, 16.5 cmn 3vs. 8.4 cmn 3, 21.9 cmn 3vs. 11.4 cmn 3, 146.1 cmn 3vs. 27.4 cmn 3, 229.6 cmn 3vs. 28.6 cmn 3; n Z=-4.242 to -2.438, all n P<0.05). The SUVn max, PSMA-TVn whole body, TL-PSMAn primary, and TL-PSMAn whole body in the GS≥8 subgroup were significantly higher than those in the GS<8 subgroup (14.8n vs. 9.9, 23.9 cmn 3vs. 14.3 cmn 3, 146.1 cmn 3vs. 36.3 cmn 3, 229.6 cmn 3vs. 36.3 cmn 3; n Z=-2.850 to -2.074, all n P20 ng/mL subgroup were significantly higher than those in the PSA≤20 ng/mL subgroup (16.2n vs. 6.4, 24.7 cmn 3vs. 8.2 cmn 3, 41.4 cmn 3vs. 10.2 cmn 3, 253.9 cmn 3vs. 28.0 cmn 3, 361.5 cmn 3vs. 29.7 cmn 3; n Z=-6.279 to-3.948, all n P<0.001). The SUVn max, PSMA-TVn primary, PSMA-TVn whole body, TL-PSMAn primary, and TL-PSMAn whole body in the clinical T3-T4 subgroup were significantly higher than those in the clinical T1-T2 subgroup (16.6 n vs. 9.3, 34.9 cmn 3vs. 10.7 cmn 3, 62.3 cmn 3vs. 14.3 cmn 3, 303.5 cmn 3vs. 32.6 cmn 3, 482.1 cmn 3vs. 45.9 cmn 3; n Z=-4.889 to-3.629, all n P<0.001).n Conclusion:The metabolic volume parameters based on n 68Ga-PSMA-11 PET/CT in metastatic and high-risk patients with newly diagnosed PCa were significantly higher than those in non-metastatic and low-medium-risk patients.n